

# COSINUS - Cohort for Evaluating Structural and Individual Factors Among Drug-Users

Head :Roux Perrine, UMR1252 (SESSTIM) INSERM

Auriacombe Marc, Sanpsy CNRS USR 3413

Jauffret-Roustide Marie, Cermes3 / Inserm U988 / CNRS UMR 8236 / EHES

Lalanne-Tongio Laurence, Inserm U1114 / CHU Strasbourg

Last update : 10/29/2020 | Version : 3 | ID : 73308

## General

### Identification

Detailed name Cohort for Evaluating Structural and Individual Factors Among Drug-Users

Sign or acronym COSINUS

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL: DR-2015-258 avis n°915054 / CCTIRS : avis n°15 021

### General Aspects

Medical area General practice  
Infectious diseases  
Psychology and psychiatry

Health determinants Addictions  
Lifestyle and behavior

### Scientific investigator(s) (Contact)

Name of the director Roux

Surname Perrine

Address Inserm U1252 SESSTIM  
IHU Infection Méditerranée  
19-21 bld Jean Moulin  
13005 Marseille

Phone +33 (0) 4 13 73 22 78

Email perrine.roux@inserm.fr

Unit UMR1252 (SESSTIM) INSERM

Organization Inserm

Name of the director Auriacombe

Surname Marc

Address CNRS USR 3413, SANPSY  
Université de Bordeaux  
121 rue de la Béchade CS 81285  
33076 BORDEAUX Cedex

Phone +33 (0) 5 56 56 17 38

Email marc.auriacombe@u-bordeaux.fr

Unit Sanpsy CNRS USR 3413

Organization INSERM

Name of the director Jauffret-Roustide

Surname Marie

Address Cermes3  
Université Paris Descartes  
45 rue des saints pères  
75006 Paris

Phone +33 (0) 6 10 55 32 87

Email marie.jauffretroustide@santepubliquefrance.fr

Unit Cermes3 / Inserm U988 / CNRS UMR 8236 / EHESS

Organization inserm

Name of the director Lalanne-Tongio

Surname Laurence

Address Inserm U1114, Pole de Psychiatrie Santé Mentale  
Addictologie  
Clinique Psychiatrique  
1 place de l'hôpital  
67000 Strasbourg

Phone +33 (0) 3 88 11 66 55

Email laurence.lalanne@chru-strasbourg.fr

Unit Inserm U1114 / CHU Strasbourg

Organization	inserm
<b>Collaborations</b>	
Participation in projects, networks and consortia	Yes
Details	COSINUS research will be conducted under the responsibility of a research consortium. The consortium will be made up of four principal investigators (P. Roux, M. Jauffret-Roustide, M. Auriacombe, L. Lalanne-Tongio); two research associates (P. Carrieri and J-M. Danion) and a scientific coucsil (H.J. Aubin, N. Chau, L. Karila, T. Kerr, M. Lejoyeux and a representative of the pulic health institute).
Others	The COSINUS project is part of the PRIMER (Preventing Injection by Modifying Existing Responses) multi-cohort project, coordinated by Daniel Werb (University of California San Diego Dept).
<b>Funding</b>	
Funding status	Public
Details	Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA)
<b>Governance of the database</b>	
Sponsor(s) or organisation(s) responsible	SESSTIM of unit UMR1252 (Marseille), CERMES3 of unit INSERM U988 (Paris), Laboratory Sanpsy CNRS USR 3413 (Bordeaux); Inserm U1114 and University hospital of Strasbourg
Organisation status	Public
Presence of scientific or steering committees	Yes
<b>Additional contact</b>	
<b>Main features</b>	
<b>Type of database</b>	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried	No

out as part of an interventional study

Additional information regarding sample selection.

Sample of 680 injecting drug users in 4 different areas throughout France (multicentric cohort) to document the outcome in 4 cities that have very different geographical and health characteristics (Bordeaux, Marseilles, Paris and Strasbourg).

## Database objective

Main objective

Objectives: The main aims of this study are to assess the impact of structural factors (e.g. attendance at CAARUD [Reduction Support Centres for Drug Users] and CSAPA [Specialised Addiction Treatment Support and Prevention Centres]; prison; other environmental factors) and individual traits (personal history; sociodemographic factors; substance use; addictive disorder; other comorbidities) on trends in drug use, practices and treatment path; drug-user social circumstances, experience of violence and drug-related offences. Secondary aims involve drawing a map of the socio-behavioural situation of drug users; estimating the prevalence of specific drug use within the sample and to better understand the needs of drug users for treating addiction and also for screening and the management of disorders associated with drug use.

Inclusion criteria

Inclusion criteria includes: regular users of illicit substances or diverted pharmaceuticals, who have injected drugs at least once within the last month; over 18 years old.

## Population type

Age

Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)

Population covered

Sick population

Pathology

F10-F19 - Mental and behavioural disorders due to psychoactive substance use

Gender

Male  
Woman  
Other

Geography area

National

Detail of the geography area      Bordeaux, Marseilles, Paris, Strasbourg

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY)      2016

Date of last collection (YYYY or MM/YYYY)      2019

### Size of the database

Size of the database (number of individuals)      [500-1000[ individuals

Details of the number of individuals      680

### Data

Database activity      Data collection completed

Type of data collected      Declarative data

Declarative data (detail)      Face to face interview

Details of collected declarative data      Sociodemographic data; history of drug use (only at baseline); current use; reasons for use; at-risk practices of drug use and other risk practices; treatment path; experience of prison or violence; requirements in terms of management and prevention.

Presence of a biobank      No

Health parameters studied      Health event/morbidity  
Health care consumption and services  
Quality of life/health perception

Care consumption (detail)      Medical/paramedical consultation

### Procedures

Data collection method      Face-to-face interview.

Participant monitoring      Yes

Monitoring procedures      Monitoring by contact with the participant (mail, e-mail, telephone etc.)  
Monitoring by convocation of the participant

Details on monitoring of participants	Each participant will be followed up for 12 months with a face-to-face interview at baseline, 3, 6 and 12 months.
---------------------------------------	---

Links to administrative sources	No
---------------------------------	----

## Promotion and access

### Promotion

Link to the document	<a href="https://doi.org/10.1136/bmjopen-2018-023683">10.1136/bmjopen-2018-023683</a>
----------------------	---

### Access

Presence of document that lists variables and coding procedures	Yes
---	-----

Terms of data access (charter for data provision, format of data, availability delay)	Contact the scientist in charge (perrine.roux@inserm.fr)
---	--

Access to aggregated data	Access on specific project only
---------------------------	---------------------------------

Access to individual data	Access on specific project only
---------------------------	---------------------------------